Carcinogenesis, Vol. 21, No. 4, 585-591,
April 2000
© 2000 Oxford University Press
Cancer Biology |
Development of a syngeneic mouse model for events related to ovarian cancer
1 Department of Anatomy and Cell Biology,
2 Department of Molecular and Integrative Physiology,
3 Department of Pathology and Laboratory Medicine and
4 Department of Obstetrics and Gynecology, University of Kansas Medical Center, Center for Reproductive Sciences, Kansas City, KS 66160, USA
Mouse ovarian surface epithelial cells (MOSEC) were obtained from virgin, mature mice by mild trypsinization and were repeatedly passaged in vitro. Early passage cells (<20 passages) exhibited a cobblestone morphology and contact inhibition of growth. After ~20 passages in vitro, cobblestone morphology and contact inhibition of growth was lost. Tumor forming potential was determined by s.c. and i.p. injection of early and late passage cells into athymic and syngeneic C57BL6 mice. Subcutaneous tumors formed in ~4 months and were present only at the injection site. Intraperitoneal injection of late passage MOSEC into athymic and syngeneic mice resulted in growth of tumor implants throughout the abdominal cavity, and production of hemorrhagic ascitic fluid. Early passage MOSEC did not form tumors in vivo. Histopathologic analysis of tumors revealed a highly malignant neoplasm containing both carcinomatous and sarcomatous components. Late passage MOSEC expressed cytokeratin and did not produce ovarian steroids in response to gonadotropin stimulation in vitro. Ten clonal lines were established from late passage MOSEC. Each clone formed multiple peritoneal tumors and ascitic fluid after i.p. injection into C57BL6 mice. Three cell lines examined cytogenetically were polyploid with near-tetraploid modal chromosome numbers. Common clonal chromosome gains and losses included +5, +15, +19 and –X, –3, –4. One cell line had a clonal translocation between chromosomes 15 and 18 and another had a small marker chromosome; common structural abnormalities were not observed. These data describe the development of a mouse model for the study of events related to ovarian cancer in humans. The ability of the MOSEC to form extensive tumors within the peritoneal cavity, similar to those seen in women with Stage III and IV cancer, and the ability of the MOSEC to produce tumors in mice with intact immune systems, makes this model unique for investigations of molecular and immune interactions in ovarian cancer development.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Zeng, H. Li, Y. Liu, Z. Zhang, Y. Zhang, and R. Yang Tumor-Induced Suppressor of Cytokine Signaling 3 Inhibits Toll-like Receptor 3 Signaling in Dendritic Cells via Binding to Tyrosine Kinase 2 Cancer Res., July 1, 2008; 68(13): 5397 - 5404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hagemann, T. Lawrence, I. McNeish, K. A. Charles, H. Kulbe, R. G. Thompson, S. C. Robinson, and F. R. Balkwill "Re-educating" tumor-associated macrophages by targeting NF-{kappa}B J. Exp. Med., June 9, 2008; 205(6): 1261 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Tash, R. Chakrasali, S. R. Jakkaraj, J. Hughes, S. K. Smith, K. Hornbaker, L. L. Heckert, S. B. Ozturk, M. K. Hadden, T. G. Kinzy, et al. Gamendazole, an Orally Active Indazole Carboxylic Acid Male Contraceptive Agent, Targets HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A), and Stimulates Il1a Transcription in Rat Sertoli Cells Biol Reprod, June 1, 2008; 78(6): 1139 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Barber, T. Zhang, and C. L. Sentman Immunotherapy with Chimeric NKG2D Receptors Leads to Long-Term Tumor-Free Survival and Development of Host Antitumor Immunity in Murine Ovarian Cancer J. Immunol., January 1, 2008; 180(1): 72 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yang, E. M. Wall, K. Milne, P. Theiss, P. Watson, and B. H. Nelson CD8+ T Cells Induce Complete Regression of Advanced Ovarian Cancers by an Interleukin (IL)-2/IL-15 Dependent Mechanism Clin. Cancer Res., December 1, 2007; 13(23): 7172 - 7180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Zhang, A. Barber, and C. L. Sentman Chimeric NKG2D Modified T Cells Inhibit Systemic T-Cell Lymphoma Growth in a Manner Involving Multiple Cytokines and Cytotoxic Pathways Cancer Res., November 15, 2007; 67(22): 11029 - 11036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-L. Chang, Y.-C. Tsai, L. He, T.-C. Wu, and C.-F. Hung Cancer Immunotherapy Using Irradiated Tumor Cells Secreting Heat Shock Protein 70 Cancer Res., October 15, 2007; 67(20): 10047 - 10057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Said, M. J. Socha, J. J. Olearczyk, A. A. Elmarakby, J. D. Imig, and K. Motamed Normalization of the Ovarian Cancer Microenvironment by SPARC Mol. Cancer Res., October 1, 2007; 5(10): 1015 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Stewart and S. I. Abrams Altered Immune Function during Long-Term Host-Tumor Interactions Can Be Modulated to Retard Autochthonous Neoplastic Growth J. Immunol., September 1, 2007; 179(5): 2851 - 2859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Kumar Multiple Ovulations, Ovarian Epithelial Inclusion Cysts, and It'SMAD Two! Endocrinology, August 1, 2007; 148(8): 3591 - 3594. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Burdette, R. M. Oliver, V. Ulyanov, S. M. Kilen, K. E. Mayo, and T. K. Woodruff Ovarian Epithelial Inclusion Cysts in Chronically Superovulated CD1 and Smad2 Dominant-Negative Mice Endocrinology, August 1, 2007; 148(8): 3595 - 3604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Wall, K. Milne, M. L. Martin, P. H. Watson, P. Theiss, and B. H. Nelson Spontaneous Mammary Tumors Differ Widely in Their Inherent Sensitivity to Adoptively Transferred T Cells Cancer Res., July 1, 2007; 67(13): 6442 - 6450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hagemann, S. C. Robinson, R. G. Thompson, K. Charles, H. Kulbe, and F. R. Balkwill Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis Mol. Cancer Ther., July 1, 2007; 6(7): 1993 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Robinson-Smith, I. Isaacsohn, C. A. Mercer, M. Zhou, N. Van Rooijen, N. Husseinzadeh, M. M. McFarland-Mancini, and A. F. Drew Macrophages Mediate Inflammation-Enhanced Metastasis of Ovarian Tumors in Mice Cancer Res., June 15, 2007; 67(12): 5708 - 5716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Choi, A. S. T. Wong, H.-F. Huang, and P. C. K. Leung Gonadotropins and Ovarian Cancer Endocr. Rev., June 1, 2007; 28(4): 440 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Bak, J. J. Walters, M. Takeya, J. R. Conejo-Garcia, and B. L. Berwin Scavenger Receptor-A-Targeted Leukocyte Depletion Inhibits Peritoneal Ovarian Tumor Progression Cancer Res., May 15, 2007; 67(10): 4783 - 4789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Barber, T. Zhang, L. R. DeMars, J. Conejo-Garcia, K. F. Roby, and C. L. Sentman Chimeric NKG2D Receptor-Bearing T Cells as Immunotherapy for Ovarian Cancer Cancer Res., May 15, 2007; 67(10): 5003 - 5008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhang, X. Yang, Y. Zhang, B. Zeng, S. Wang, T. Zhu, R. B.S. Roden, Y. Chen, and R. Yang Delivery of Telomerase Reverse Transcriptase Small Interfering RNA in Complex with Positively Charged Single-Walled Carbon Nanotubes Suppresses Tumor Growth. Clin. Cancer Res., August 15, 2006; 12(16): 4933 - 4939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Yang, Z. Cai, Y. Zhang, W. H. Yutzy IV, K. F. Roby, and R. B.S. Roden CD80 in Immune Suppression by Mouse Ovarian Carcinoma-Associated Gr-1+CD11b+ Myeloid Cells. Cancer Res., July 1, 2006; 66(13): 6807 - 6815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, J. Huang, N. Yang, S. Liang, A. Barchetti, A. Giannakakis, M. G. Cadungog, A. O'Brien-Jenkins, M. Massobrio, K. F. Roby, et al. Integrative Genomic Analysis of Protein Kinase C (PKC) Family Identifies PKC{iota} as a Biomarker and Potential Oncogene in Ovarian Carcinoma. Cancer Res., May 1, 2006; 66(9): 4627 - 4635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hagemann, J. Wilson, F. Burke, H. Kulbe, N. F. Li, A. Pluddemann, K. Charles, S. Gordon, and F. R. Balkwill Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J. Immunol., April 15, 2006; 176(8): 5023 - 5032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bazzaro, M. K. Lee, A. Zoso, W. L.H. Stirling, A. Santillan, I.-M. Shih, and R. B.S. Roden Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res., April 1, 2006; 66(7): 3754 - 3763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Bristol-Gould, C. G. Hutten, C. Sturgis, S. M. Kilen, K. E. Mayo, and T. K. Woodruff The Development of a Mouse Model of Ovarian Endosalpingiosis Endocrinology, December 1, 2005; 146(12): 5228 - 5236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Said and K. Motamed Absence of Host-Secreted Protein Acidic and Rich in Cysteine (SPARC) Augments Peritoneal Ovarian Carcinomatosis Am. J. Pathol., December 1, 2005; 167(6): 1739 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. George, T. Chen, and C. C. Taylor Src Tyrosine Kinase and Multidrug Resistance Protein-1 Inhibitions Act Independently but Cooperatively to Restore Paclitaxel Sensitivity to Paclitaxel-Resistant Ovarian Cancer Cells Cancer Res., November 15, 2005; 65(22): 10381 - 10388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Murdoch Carcinogenic Potential of Ovulatory Genotoxicity Biol Reprod, October 1, 2005; 73(4): 586 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Murdoch, E. A. Van Kirk, and B. M. Alexander DNA Damages in Ovarian Surface Epithelial Cells of Ovulatory Hens Experimental Biology and Medicine, June 1, 2005; 230(6): 429 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Chen, Y. Pengetnze, and C. C. Taylor Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3 Mol. Cancer Ther., February 1, 2005; 4(2): 217 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Steller, T. J. Shaw, B. C. Vanderhyden, and J.-F. Ethier Inhibin Resistance Is Associated with Aggressive Tumorigenicity of Ovarian Cancer Cells Mol. Cancer Res., January 1, 2005; 3(1): 50 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Tseng, A. Hurtado, H. Yee, B. Levin, C. Boivin, M. Benet, S. V. Blank, A. Pellicer, and D. Meruelo Using Sindbis Viral Vectors for Specific Detection and Suppression of Advanced Ovarian Cancer in Animal Models Cancer Res., September 15, 2004; 64(18): 6684 - 6692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, G. Yang, J. A. Thompson-Lanza, A. Glassman, K. Hayes, A. Patterson, R. T. Marquez, N. Auersperg, Y. Yu, W. C. Hahn, et al. A Genetically Defined Model for Human Ovarian Cancer Cancer Res., March 1, 2004; 64(5): 1655 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Piechocki, Y.-S. Ho, S. Pilon, and W.-Z. Wei Human ErbB-2 (Her-2) Transgenic Mice: A Model System for Testing Her-2 Based Vaccines J. Immunol., December 1, 2003; 171(11): 5787 - 5794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, N. Yang, J.-W. Park, D. Katsaros, S. Fracchioli, G. Cao, A. O'Brien-Jenkins, T. C. Randall, S. C. Rubin, and G. Coukos Tumor-derived Vascular Endothelial Growth Factor Up-Regulates Angiopoietin-2 in Host Endothelium and Destabilizes Host Vasculature, Supporting Angiogenesis in Ovarian Cancer Cancer Res., June 15, 2003; 63(12): 3403 - 3412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Garson, E. Macdonald, M. Dube, R. Bao, T. C. Hamilton, and B. C. Vanderhyden Generation of Tumors in Transgenic Mice Expressing the SV40 T Antigen Under the Control of Ovarian-Specific Promoter 1 Reproductive Sciences, May 1, 2003; 10(4): 244 - 250. [Abstract] [PDF]
|
|
|
|
|
|
D. C. Connolly, R. Bao, A. Y. Nikitin, K. C. Stephens, T. W. Poole, X. Hua, S. S. Harris, B. C. Vanderhyden, and T. C. Hamilton Female Mice Chimeric for Expression of the Simian Virus 40 TAg under Control of the MISIIR Promoter Develop Epithelial Ovarian Cancer Cancer Res., March 15, 2003; 63(6): 1389 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Brewer, K. Johnson, M. Follen, D. Gershenson, and R. Bast Jr. Prevention of Ovarian Cancer: Intraepithelial Neoplasia Clin. Cancer Res., January 1, 2003; 9(1): 20 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, N. Yang, J.-R. Conejo Garcia, A. Mohamed, F. Benencia, S. C. Rubin, D. Allman, and G. Coukos Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma Am. J. Pathol., December 1, 2002; 161(6): 2295 - 2309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bao, D. C. Connolly, M. Murphy, J. Green, J. K. Weinstein, D. A. Pisarcik, and T. C. Hamilton Activation of Cancer-Specific Gene Expression by the Survivin Promoter J Natl Cancer Inst, April 3, 2002; 94(7): 522 - 528. [Abstract] [Full Text] [PDF]
|
|